It's been a good week for Sigma Healthcare Limited (ASX:SIG) shareholders, because the company has just released its latest yearly results, and the shares gained 9.5% to AU$3.12. Sigma Healthcare reported AU$6.0b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of AU$0.051 beat expectations, being 7.9% higher than what the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.ASX:SIG Earnings and Revenue Growth August 29th 2025

Taking into account the latest results, the current consensus from Sigma Healthcare's eight analysts is for revenues of AU$10.4b in 2026. This would reflect a sizeable 74% increase on its revenue over the past 12 months. Per-share earnings are expected to jump 36% to AU$0.062. Before this earnings report, the analysts had been forecasting revenues of AU$9.66b and earnings per share (EPS) of AU$0.06 in 2026. So there seems to have been a moderate uplift in sentiment following the latest results, given the upgrades to both revenue and earnings per share forecasts for next year.

Check out our latest analysis for Sigma Healthcare

Despite these upgrades,the analysts have not made any major changes to their price target of AU$3.01, suggesting that the higher estimates are not likely to have a long term impact on what the stock is worth. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Sigma Healthcare analyst has a price target of AU$3.40 per share, while the most pessimistic values it at AU$2.45. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting Sigma Healthcare's growth to accelerate, with the forecast 74% annualised growth to the end of 2026 ranking favourably alongside historical growth of 17% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 11% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Sigma Healthcare to grow faster than the wider industry.

Story Continues

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Sigma Healthcare following these results. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. The consensus price target held steady at AU$3.01, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Sigma Healthcare going out to 2028, and you can see them free on our platform here..

Plus, you should also learn about the  1 warning sign  we've spotted with Sigma Healthcare .

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments